{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T23:29:04Z","timestamp":1792020544265,"version":"4.4.0"},"reference-count":120,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["201803040002"],"award-info":[{"award-number":["201803040002"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81701989"],"award-info":[{"award-number":["81701989"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81730060"],"award-info":[{"award-number":["81730060"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Virology"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.coviro.2019.04.004","type":"journal-article","created":{"date-parts":[[2019,5,25]],"date-time":"2019-05-25T00:54:59Z","timestamp":1558745699000},"page":"21-30","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["Development of CAR-T cells for long-term eradication and surveillance of HIV-1 reservoir"],"prefix":"10.1016","volume":"38","author":[{"given":"Bingfeng","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coviro.2019.04.004_bib0005","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/nm880","article-title":"Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells","volume":"9","author":"Siliciano","year":"2003","journal-title":"Nat Med"},{"key":"10.1016\/j.coviro.2019.04.004_bib0010","doi-asserted-by":"crossref","first-page":"4819","DOI":"10.1073\/pnas.0736332100","article-title":"Heterogeneous clearance rates of long-lived lymphocytes infected with HIV: intrinsic stability predicts lifelong persistence","volume":"100","author":"Strain","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coviro.2019.04.004_bib0015","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.immuni.2018.04.030","article-title":"Targeting the latent reservoir for HIV-1","volume":"48","author":"Sengupta","year":"2018","journal-title":"Immunity"},{"key":"10.1016\/j.coviro.2019.04.004_bib0020","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/nrmicro.2015.5","article-title":"Hiv reservoirs: what, where and how to target them","volume":"14","author":"Churchill","year":"2016","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.coviro.2019.04.004_bib0025","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/nm.3445","article-title":"HIV-1 persistence in CD4+ T cells with stem cell-like properties","volume":"20","author":"Buzon","year":"2014","journal-title":"Nat Med"},{"key":"10.1016\/j.coviro.2019.04.004_bib0030","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1172\/JCI116016","article-title":"Activation of infectious virus from latent human immunodeficiency virus infection of monocytes in vivo","volume":"90","author":"Mikovits","year":"1992","journal-title":"J Clin Investig"},{"key":"10.1016\/j.coviro.2019.04.004_bib0035","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1126\/science.274.5289.985","article-title":"Quantitative image analysis of HIV-1 infection in lymphoid tissue","volume":"274","author":"Haase","year":"1996","journal-title":"Science (New York, NY)"},{"key":"10.1016\/j.coviro.2019.04.004_bib0040","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s12977-017-0344-7","article-title":"A mature macrophage is a principal HIV-1 cellular reservoir in humanized mice after treatment with long acting antiretroviral therapy","volume":"14","author":"Arainga","year":"2017","journal-title":"Retrovirology"},{"key":"10.1016\/j.coviro.2019.04.004_bib0045","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1128\/JVI.79.1.602-608.2005","article-title":"Long-term productive human immunodeficiency virus infection of CD1a-sorted myeloid dendritic cells","volume":"79","author":"Popov","year":"2005","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2019.04.004_bib0050","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/nm.2109","article-title":"HIV-1 infects multipotent progenitor cells causing cell death and establishing latent cellular reservoirs","volume":"16","author":"Carter","year":"2010","journal-title":"Nat Med"},{"key":"10.1016\/j.coviro.2019.04.004_bib0055","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1002286","article-title":"HIV-1 replication in the central nervous system occurs in two distinct cell types","volume":"7","author":"Schnell","year":"2011","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coviro.2019.04.004_bib0060","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1016\/S0140-6736(13)60104-X","article-title":"Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs","volume":"381","author":"Katlama","year":"2013","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.coviro.2019.04.004_bib0065","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1186\/s12916-015-0517-y","article-title":"HIV-1 functional cure: will the dream come true?","volume":"13","author":"Liu","year":"2015","journal-title":"BMC Med"},{"key":"10.1016\/j.coviro.2019.04.004_bib0070","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005142","article-title":"The depsipeptide romidepsin reverses HIV-1 latency in vivo","volume":"11","author":"Sogaard","year":"2015","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coviro.2019.04.004_bib0075","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/nature11286","article-title":"Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy","volume":"487","author":"Archin","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.coviro.2019.04.004_bib0080","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1093\/jac\/dkt338","article-title":"Unique characteristics of histone deacetylase inhibitors in reactivation of latent HIV-1 in Bcl-2-transduced primary resting CD4+ T cells","volume":"69","author":"Shan","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.coviro.2019.04.004_bib0085","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/nm.3489","article-title":"New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo","volume":"20","author":"Bullen","year":"2014","journal-title":"Nat Med"},{"key":"10.1016\/j.coviro.2019.04.004_bib0090","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1093\/nar\/gks976","article-title":"The BET bromodomain inhibitor JQ1 activates HIV latency through antagonizing Brd4 inhibition of Tat-transactivation","volume":"41","author":"Li","year":"2013","journal-title":"Nucl Acids Res"},{"key":"10.1016\/j.coviro.2019.04.004_bib0095","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.phrs.2018.10.023","article-title":"T cell toxicity of HIV latency reversing agents","volume":"139","author":"Zhao","year":"2019","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.coviro.2019.04.004_bib0100","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.immuni.2012.01.014","article-title":"Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation","volume":"36","author":"Shan","year":"2012","journal-title":"Immunity"},{"key":"10.1016\/j.coviro.2019.04.004_bib0105","doi-asserted-by":"crossref","first-page":"3162","DOI":"10.3389\/fimmu.2018.03162","article-title":"Antigen production after latency reversal and expression of inhibitory receptors in CD8+ T cells limit the killing of HIV-1 reactivated cells","volume":"9","author":"Ruiz","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.coviro.2019.04.004_bib0110","doi-asserted-by":"crossref","first-page":"16168","DOI":"10.1073\/pnas.242600099","article-title":"Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells","volume":"99","author":"Yee","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coviro.2019.04.004_bib0115","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1126\/science.aaa4967","article-title":"Adoptive cell transfer as personalized immunotherapy for human cancer","volume":"348","author":"Rosenberg","year":"2015","journal-title":"Science (New York, NY)"},{"key":"10.1016\/j.coviro.2019.04.004_bib0120","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1158\/1078-0432.CCR-14-2208","article-title":"Persistence of CTL clones targeting melanocyte differentiation antigens was insufficient to mediate significant melanoma regression in humans","volume":"21","author":"Chandran","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.coviro.2019.04.004_bib0125","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/nature14053","article-title":"Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations","volume":"517","author":"Deng","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.coviro.2019.04.004_bib0130","doi-asserted-by":"crossref","first-page":"5391","DOI":"10.1182\/blood-2010-11-320226","article-title":"HIV-specific CD8+ T cells from HIV+ individuals receiving HAART can be expanded ex vivo to augment systemic and mucosal immunity in vivo","volume":"117","author":"Chapuis","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.coviro.2019.04.004_bib0135","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1182\/bloodadvances.2017012971","article-title":"The human IL-15 superagonist ALT-803 directs SIV-specific CD8(+) T cells into B-cell follicles","volume":"2","author":"Webb","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.coviro.2019.04.004_bib0140","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1172\/JCI80566","article-title":"HIV-specific CD8(+) T cells and HIV eradication","volume":"126","author":"Jones","year":"2016","journal-title":"J Clin Investig"},{"key":"10.1016\/j.coviro.2019.04.004_bib0145","doi-asserted-by":"crossref","first-page":"10024","DOI":"10.1073\/pnas.86.24.10024","article-title":"Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity","volume":"86","author":"Gross","year":"1989","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coviro.2019.04.004_bib0150","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1073\/pnas.90.2.720","article-title":"Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors","volume":"90","author":"Eshhar","year":"1993","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coviro.2019.04.004_bib0155","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1517\/14712598.2015.1046430","article-title":"Trucks: the fourth generation of cars","volume":"15","author":"Chmielewski","year":"2015","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.coviro.2019.04.004_bib0160","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coviro.2019.04.004_bib0165","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coviro.2019.04.004_bib0170","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coviro.2019.04.004_bib0175","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric antigen receptor T cells in refractory B-cell lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coviro.2019.04.004_bib0180","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1126\/science.aar6711","article-title":"Car T cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.coviro.2019.04.004_bib0185","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1001\/jama.2017.15218","article-title":"FDA approval of tisagenlecleucel: promise and complexities of a $475\u2009000 cancer drug","volume":"318","author":"Bach","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.coviro.2019.04.004_bib0190","first-page":"e122","article-title":"Axicabtagene ciloleucel (Yescarta) for B-cell lymphoma","volume":"60","year":"2018","journal-title":"Med Lett Drugs Ther"},{"key":"10.1016\/j.coviro.2019.04.004_bib0195","doi-asserted-by":"crossref","first-page":"3940","DOI":"10.1182\/blood-2011-10-387969","article-title":"CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results","volume":"119","author":"Till","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.coviro.2019.04.004_bib0200","first-page":"20","article-title":"CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy","volume":"24","author":"Fry","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.coviro.2019.04.004_bib0205","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1172\/JCI94306","article-title":"Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes","volume":"127","author":"Ramos","year":"2017","journal-title":"J Clin Investig"},{"key":"10.1016\/j.coviro.2019.04.004_bib0210","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.cell.2018.05.013","article-title":"Genetic inactivation of CD33 in hematopoietic stem cells to enable CAR T cell immunotherapy for acute myeloid leukemia","volume":"173","author":"Kim","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.coviro.2019.04.004_bib0215","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1200\/JCO.2018.77.8084","article-title":"T cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma","volume":"36","author":"Brudno","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.coviro.2019.04.004_bib0220","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.cell.2017.01.016","article-title":"The principles of engineering immune cells to treat cancer","volume":"168","author":"Lim","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.coviro.2019.04.004_bib0225","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1146\/annurev-med-062315-120245","article-title":"CAR T cell therapy for solid tumors","volume":"68","author":"Newick","year":"2017","journal-title":"Ann Rev Med"},{"key":"10.1016\/j.coviro.2019.04.004_bib0230","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1053\/j.gastro.2013.04.047","article-title":"T cells expressing a chimeric antigen receptor that binds hepatitis B virus envelope proteins control virus replication in mice","volume":"145","author":"Krebs","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coviro.2019.04.004_bib0235","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1136\/gutjnl-2014-308316","article-title":"Chimeric antigen receptor (CAR)-engineered T cells redirected against hepatitis C virus (HCV) E2 glycoprotein","volume":"65","author":"Sautto","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.coviro.2019.04.004_bib0240","doi-asserted-by":"crossref","first-page":"28","DOI":"10.2174\/1874357901307010028","article-title":"An influenza virus M2 protein specific chimeric antigen receptor modulates influenza A\/WSN\/33 H1N1 infection in vivo","volume":"7","author":"Talbot","year":"2013","journal-title":"Open Virol J"},{"key":"10.1016\/j.coviro.2019.04.004_bib0245","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1038\/nrclinonc.2016.36","article-title":"Driving car T-cells forward","volume":"13","author":"Jackson","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.coviro.2019.04.004_bib0250","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.1182\/blood.V84.9.2878.2878","article-title":"Targeting of human immunodeficiency virus-infected cells by CD8+ T lymphocytes armed with universal T-cell receptors","volume":"84","author":"Roberts","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.coviro.2019.04.004_bib0255","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.4049\/jimmunol.155.2.1000","article-title":"Chimeric zeta-receptors direct human natural killer (NK) effector function to permit killing of NK-resistant tumor cells and HIV-infected T lymphocytes","volume":"155","author":"Tran","year":"1995","journal-title":"J Immunol (Baltimore, Md: 1950)"},{"key":"10.1016\/j.coviro.2019.04.004_bib0260","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/sj.gt.3302413","article-title":"T-cell engineering by a chimeric T-cell receptor with antibody-type specificity for the HIV-1 gp120","volume":"12","author":"Masiero","year":"2005","journal-title":"Gene Ther"},{"key":"10.1016\/j.coviro.2019.04.004_bib0265","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/s41577-018-0042-2","article-title":"CAR T cells for infection, autoimmunity and allotransplantation","volume":"18","author":"Maldini","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.coviro.2019.04.004_bib0270","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1182\/blood.V96.3.785.015k10_785_793","article-title":"Prolonged survival and tissue trafficking following adoptive transfer of CD4zeta gene-modified autologous CD4(+) and CD8(+) T cells in human immunodeficiency virus-infected subjects","volume":"96","author":"Mitsuyasu","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.coviro.2019.04.004_bib0275","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1006\/mthe.2002.0611","article-title":"A phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy","volume":"5","author":"Deeks","year":"2002","journal-title":"Mol Ther"},{"key":"10.1016\/j.coviro.2019.04.004_bib0280","first-page":"467","article-title":"Long-term in vivo survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection","volume":"96","author":"Walker","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.coviro.2019.04.004_bib0285","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3003761","article-title":"Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells","volume":"4","author":"Scholler","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.coviro.2019.04.004_bib0290","doi-asserted-by":"crossref","first-page":"899","DOI":"10.2217\/imt.12.91","article-title":"Safety and stability of retrovirally transduced chimeric antigen receptor T cells","volume":"4","author":"Colovos","year":"2012","journal-title":"Immunotherapy"},{"key":"10.1016\/j.coviro.2019.04.004_bib0295","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1073\/pnas.0813101106","article-title":"Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains","volume":"106","author":"Carpenito","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coviro.2019.04.004_bib0300","doi-asserted-by":"crossref","first-page":"10995","DOI":"10.1158\/0008-5472.CAN-06-0160","article-title":"CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells","volume":"66","author":"Kowolik","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.coviro.2019.04.004_bib0305","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1006613","article-title":"Supraphysiologic control over HIV-1 replication mediated by CD8 T cells expressing a re-engineered CD4-based chimeric antigen receptor","volume":"13","author":"Leibman","year":"2017","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coviro.2019.04.004_bib0310","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.immuni.2016.02.023","article-title":"Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells","volume":"44","author":"Kawalekar","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.coviro.2019.04.004_bib0315","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/jmp.12137","article-title":"A novel real-time CTL assay to measure designer T-cell function against HIV Env(+) cells","volume":"43","author":"MacLean","year":"2014","journal-title":"J Med Primatol"},{"key":"10.1016\/j.coviro.2019.04.004_bib0320","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005983","article-title":"Potent and broad inhibition of HIV-1 by a peptide from the gp41 heptad repeat-2 domain conjugated to the CXCR4 amino terminus","volume":"12","author":"Leslie","year":"2016","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coviro.2019.04.004_bib0325","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1038\/mt.2015.102","article-title":"HIV-specific immunity derived from chimeric antigen receptor-engineered stem cells","volume":"23","author":"Zhen","year":"2015","journal-title":"Mol Ther"},{"key":"10.1016\/j.coviro.2019.04.004_bib0330","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1126\/science.1192819","article-title":"Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01","volume":"329","author":"Zhou","year":"2010","journal-title":"Science (New York, NY)"},{"key":"10.1016\/j.coviro.2019.04.004_bib0335","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1126\/science.1207227","article-title":"Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding","volume":"333","author":"Scheid","year":"2011","journal-title":"Science (New York, NY)"},{"key":"10.1016\/j.coviro.2019.04.004_bib0340","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/nature11544","article-title":"Broad and potent neutralization of HIV-1 by a gp41-specific human antibody","volume":"491","author":"Huang","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.coviro.2019.04.004_bib0345","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1038\/nature13601","article-title":"Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface","volume":"515","author":"Huang","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.coviro.2019.04.004_bib0350","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.immuni.2017.04.011","article-title":"Virus-like particles identify an HIV V1V2 apex-binding neutralizing antibody that lacks a protruding loop","volume":"46","author":"Cale","year":"2017","journal-title":"Immunity"},{"key":"10.1016\/j.coviro.2019.04.004_bib0355","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/978-981-13-0484-2_4","article-title":"Structural features of broadly neutralizing antibodies and rational design of vaccine","volume":"1075","author":"Zhou","year":"2018","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.coviro.2019.04.004_bib0360","doi-asserted-by":"crossref","first-page":"9712","DOI":"10.1128\/JVI.00852-16","volume":"90","author":"Liu","year":"2016","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2019.04.004_bib0365","doi-asserted-by":"crossref","first-page":"6999","DOI":"10.1128\/JVI.00805-16","article-title":"HIV-1-specific chimeric antigen receptors based on broadly neutralizing antibodies","volume":"90","author":"Ali","year":"2016","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2019.04.004_bib0370","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.ymthe.2016.12.023","article-title":"Engineering HIV-resistant, anti-HIV chimeric antigen receptor T cells","volume":"25","author":"Hale","year":"2017","journal-title":"Mol Ther"},{"key":"10.1016\/j.coviro.2019.04.004_bib0375","doi-asserted-by":"crossref","first-page":"6685","DOI":"10.1128\/JVI.00474-15","article-title":"Novel CD4-based bispecific chimeric antigen receptor designed for enhanced anti-HIV potency and absence of HIV entry receptor activity","volume":"89","author":"Liu","year":"2015","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2019.04.004_bib0380","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.jcyt.2017.11.001","article-title":"Bispecific chimeric antigen receptors targeting the CD4 binding site and high-mannose glycans of gp120 optimized for anti-human immunodeficiency virus potency and breadth with minimal immunogenicity","volume":"20","author":"Ghanem","year":"2018","journal-title":"Cytotherapy"},{"key":"10.1016\/j.coviro.2019.04.004_bib0385","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jim.2016.03.005","article-title":"Measuring IL-6 and sIL-6R in serum from patients treated with tocilizumab and\/or siltuximab following CAR T cell therapy","volume":"434","author":"Chen","year":"2016","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.coviro.2019.04.004_bib0390","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/nature21405","article-title":"Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection","volume":"543","author":"Eyquem","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.coviro.2019.04.004_bib0395","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1126\/science.276.5319.1719","article-title":"HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia","volume":"276","author":"Bonini","year":"1997","journal-title":"Science (New York, NY)"},{"key":"10.1016\/j.coviro.2019.04.004_bib0400","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1182\/blood-2007-02-072843","article-title":"Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes","volume":"110","author":"Quintarelli","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.coviro.2019.04.004_bib0405","doi-asserted-by":"crossref","first-page":"378","DOI":"10.7150\/jca.2.378","article-title":"Suicide gene therapy to increase the safety of chimeric antigen receptor-redirected T lymphocytes","volume":"2","author":"Casucci","year":"2011","journal-title":"J Cancer"},{"key":"10.1016\/j.coviro.2019.04.004_bib0410","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1084\/jem.20121932","article-title":"Follicular helper T cells serve as the major CD4 T cell compartment for HIV-1 infection, replication, and production","volume":"210","author":"Perreau","year":"2013","journal-title":"J Exp Med"},{"key":"10.1016\/j.coviro.2019.04.004_bib0415","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1038\/nm.4113","article-title":"PD-1(+) and follicular helper T cells are responsible for persistent HIV-1 transcription in treated aviremic individuals","volume":"22","author":"Banga","year":"2016","journal-title":"Nat Med"},{"key":"10.1016\/j.coviro.2019.04.004_bib0420","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/S0092-8674(00)81798-5","article-title":"A putative chemokine receptor, BLR1, directs B cell migration to defined lymphoid organs and specific anatomic compartments of the spleen","volume":"87","author":"Forster","year":"1996","journal-title":"Cell"},{"key":"10.1016\/j.coviro.2019.04.004_bib0425","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/35018581","article-title":"A chemokine-driven positive feedback loop organizes lymphoid follicles","volume":"406","author":"Ansel","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.coviro.2019.04.004_bib0430","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/nm.3781","article-title":"B cell follicle sanctuary permits persistent productive simian immunodeficiency virus infection in elite controllers","volume":"21","author":"Fukazawa","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.coviro.2019.04.004_bib0435","doi-asserted-by":"crossref","first-page":"3458","DOI":"10.1016\/j.celrep.2017.11.075","article-title":"HIV-specific CD8(+) T cells exhibit reduced and differentially regulated cytolytic activity in lymphoid tissue","volume":"21","author":"Reuter","year":"2017","journal-title":"Cell Rep"},{"key":"10.1016\/j.coviro.2019.04.004_bib0440","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1182\/blood-2008-12-195792","article-title":"Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired","volume":"114","author":"Ahmadzadeh","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.coviro.2019.04.004_bib0445","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.immuni.2016.05.001","article-title":"Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation","volume":"44","author":"Anderson Ana","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.coviro.2019.04.004_bib0450","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1158\/0008-5472.CAN-11-1620","article-title":"Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T cell function to promote tumoral immune escape","volume":"72","author":"Woo","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.coviro.2019.04.004_bib0455","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1172\/JCI80445","article-title":"TIGIT and PD-1 impair tumor antigen-specific CD8+ T cells in melanoma patients","volume":"125","author":"Chauvin","year":"2015","journal-title":"J Clin Invest"},{"key":"10.1016\/j.coviro.2019.04.004_bib0460","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.02507-16","article-title":"CXCR5-dependent entry of CD8 T cells into rhesus macaque B-cell follicles achieved through T-cell engineering","volume":"91","author":"Ayala","year":"2017","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2019.04.004_bib0465","doi-asserted-by":"crossref","first-page":"492","DOI":"10.3389\/fimmu.2018.00492","article-title":"Simian immunodeficiency virus (SIV)-specific chimeric antigen receptor-T cells engineered to target B cell follicles and suppress SIV replication","volume":"9","author":"Haran","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.coviro.2019.04.004_bib0470","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1038\/nm1482","article-title":"Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction","volume":"12","author":"Trautmann","year":"2006","journal-title":"Nat Med"},{"key":"10.1016\/j.coviro.2019.04.004_bib0475","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/nature07662","article-title":"Enhancing SIV-specific immunity in vivo by PD-1 blockade","volume":"458","author":"Velu","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.coviro.2019.04.004_bib0480","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/ni.1679","article-title":"Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection","volume":"10","author":"Blackburn","year":"2009","journal-title":"Nat Immunol"},{"key":"10.1016\/j.coviro.2019.04.004_bib0485","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s11904-017-0353-0","article-title":"Long-acting antiretrovirals: where are we now?","volume":"14","author":"Nyaku","year":"2017","journal-title":"Curr HIV\/AIDS Rep"},{"key":"10.1016\/j.coviro.2019.04.004_bib0490","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/clpt.2014.118","article-title":"A compartmental pharmacokinetic evaluation of long-acting rilpivirine in HIV-negative volunteers for pre-exposure prophylaxis","volume":"96","author":"Jackson","year":"2014","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.coviro.2019.04.004_bib0495","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1016\/S0140-6736(17)31917-7","article-title":"Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial","volume":"390","author":"Margolis","year":"2017","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.coviro.2019.04.004_bib0500","doi-asserted-by":"crossref","first-page":"4190","DOI":"10.1128\/AAC.05036-14","article-title":"Oral administration of the nucleoside EFdA (4\u2032-ethynyl-2-fluoro-2\u2032-deoxyadenosine) provides rapid suppression of HIV viremia in humanized mice and favorable pharmacokinetic properties in mice and the rhesus macaque","volume":"59","author":"Stoddart","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coviro.2019.04.004_bib0505","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01058-18","article-title":"Extended-duration MK-8591-eluting implant as a candidate for HIV treatment and prevention","volume":"62","author":"Barrett","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coviro.2019.04.004_bib0510","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/nature11604","article-title":"HIV therapy by a combination of broadly neutralizing antibodies in humanized mice","volume":"492","author":"Klein","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.coviro.2019.04.004_bib0515","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/nature12744","article-title":"Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys","volume":"503","author":"Barouch","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.coviro.2019.04.004_bib0520","doi-asserted-by":"crossref","first-page":"16538","DOI":"10.1073\/pnas.1315295110","article-title":"Hiv-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice","volume":"110","author":"Horwitz","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coviro.2019.04.004_bib0525","doi-asserted-by":"crossref","first-page":"13151","DOI":"10.1073\/pnas.1414148111","article-title":"Broadly neutralizing antibodies suppress HIV in the persistent viral reservoir","volume":"111","author":"Chun","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coviro.2019.04.004_bib0530","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1084\/jem.20131244","article-title":"Broadly neutralizing antibodies that inhibit HIV-1 cell to cell transmission","volume":"210","author":"Malbec","year":"2013","journal-title":"J Exp Med"},{"key":"10.1016\/j.coviro.2019.04.004_bib0535","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/nature14411","article-title":"Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117","volume":"522","author":"Caskey","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.coviro.2019.04.004_bib0540","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aad5752","article-title":"Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection","volume":"7","author":"Lynch","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.coviro.2019.04.004_bib0545","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1056\/NEJMoa1608243","article-title":"Effect of HIV antibody VRC01 on viral rebound after treatment interruption","volume":"375","author":"Bar","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coviro.2019.04.004_bib0550","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/nature18929","article-title":"HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption","volume":"535","author":"Scheid","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.coviro.2019.04.004_bib0555","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/s41586-018-0531-2","article-title":"Combination therapy with anti-HIV-1 antibodies maintains viral suppression","volume":"561","author":"Mendoza","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.coviro.2019.04.004_bib0560","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1182\/blood-2002-09-2800","article-title":"Persistence and expression of the adenosine deaminase gene for 12 years and immune reaction to gene transfer components: long-term results of the first clinical gene therapy trial","volume":"101","author":"Muul","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.coviro.2019.04.004_bib0565","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood-2009-08-239186","article-title":"Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients","volume":"115","author":"Heslop","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.coviro.2019.04.004_bib0570","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1182\/blood-2011-07-366419","article-title":"Generation of CD19-chimeric antigen receptor modified CD8+ T cells derived from virus-specific central memory T cells","volume":"119","author":"Terakura","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.coviro.2019.04.004_bib0575","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1182\/blood-2015-12-686725","article-title":"Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL","volume":"127","author":"Wang","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.coviro.2019.04.004_bib0580","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1038\/mt.2009.83","article-title":"Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo","volume":"17","author":"Milone","year":"2009","journal-title":"Mol Ther"},{"key":"10.1016\/j.coviro.2019.04.004_bib0585","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41586-018-0178-z","article-title":"Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells","volume":"558","author":"Fraietta","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.coviro.2019.04.004_bib0590","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/s41586-019-0985-x","article-title":"NR4A transcription factors limit CAR T cell function in solid tumours","volume":"567","author":"Chen","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.coviro.2019.04.004_bib0595","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1006753","article-title":"Long-term persistence and function of hematopoietic stem cell-derived chimeric antigen receptor T cells in a nonhuman primate model of HIV\/AIDS","volume":"13","author":"Zhen","year":"2017","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coviro.2019.04.004_bib0600","doi-asserted-by":"crossref","DOI":"10.1038\/mto.2016.15","article-title":"Clinical manufacturing of CAR T cells: foundation of a promising therapy","volume":"3","author":"Wang","year":"2016","journal-title":"Mol Ther Oncolytics"}],"container-title":["Current Opinion in Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879625719300203?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879625719300203?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T21:21:06Z","timestamp":1783632066000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879625719300203"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":120,"alternative-id":["S1879625719300203"],"URL":"https:\/\/doi.org\/10.1016\/j.coviro.2019.04.004","relation":{},"ISSN":["1879-6257"],"issn-type":[{"value":"1879-6257","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of CAR-T cells for long-term eradication and surveillance of HIV-1 reservoir","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coviro.2019.04.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}